Mental Health Clinics in Dyersburg, TN Accepting Medicare
6 Mental Health Clinics found. Showing 1 - 6
 Revitalize Counseling & Consultation Services Counselor Medicare: Not Enrolled in Medicare Practice Location: 610 Isaac Hayes Dr., Dyersburg, TN 38024 Phone: 901-569-2823 |
Wellness Ambulatory Care Inc. Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 640 Us Highway 51 Byp E Ste M, Dyersburg, TN 38024 Phone: 731-285-6535 Fax: 731-285-6532 |
Bhg Xxxi, Llc Clinic - Mental Health Medicare: Medicare Enrolled Practice Location: 640 Us Highway 51 Byp E Ste M, Dyersburg, TN 38024 Phone: 731-285-6535 Fax: 731-285-6532 |
Friend Of A Friend Counseling Center Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 675 Carter Ln, Dyersburg, TN 38024 Phone: 731-676-3707 |
Phoenix Health And Wellness Social Worker - Clinical Medicare: Medicare Enrolled Practice Location: 1505 Woodlawn Ave Ste A, Dyersburg, TN 38024 Phone: 731-478-6064 Fax: 731-478-6067 |
Here's Hope Counseling Center Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 315 W Court St, Dyersburg, TN 38024 Phone: 731-287-8100 Fax: 731-287-9551 |
News Archive
Scientists use tobacco plants to create antibodies against tumor cells
Scientists at Jefferson Medical College are using tobacco plants to produce monoclonal antibodies – tiny guided protein missiles – that can target and hunt down cancer cells. The plants promise to provide a cheaper, faster method of producing anticancer antibodies, raising hopes that the technology can one day be used in humans.
FDA announces new initiative to modernize regulation of clinical trials
FDA announces new policy and regulatory developments to strengthen the Agency's oversight and protection of patients in clinical trials and the integrity of resulting data in an effort to modernize the agency's approach to bioresearch monitoring as part of the Critical Path Initiative.
Healthcare Services Group declares cash dividend
Healthcare Services Group, Inc.: Our Board of Directors has declared a regular quarterly cash dividend of $ .21 per common share, payable on March 5, 2010 to shareholders of record at the close of business February 12, 2010. This dividend represents a 5% increase over the dividend declared for the 2009 third quarter and a 24% increase over the 2008 same period payment.
CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced that it has reached the targeted enrollment of 105 evaluable patients in its international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for soft tissue sarcoma.
› Verified 6 days ago